Physician profile
Paul D Dash
NPI 1942237987
$21,179.74
in general payments reported to CMS, 2019-2025
34 companies · $97.68 in 2025
The $97.68 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $1,017 · 2021: $13K · 2022: $1,485 · 2023: $2,517 · 2024: $2,221 · 2025: $97.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,724 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,723.72 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $12,982.02 | 2019-2023 | Tysabri, Vumerity |
| Lilly USA, LLC | $1,257.36 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Abbvie INC. | $1,169.27 | 2022-2024 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $1,164.94 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Amgen INC. | $941.75 | 2019-2023 | Aimovig |
| Lundbeck LLC | $568.07 | 2021-2024 | Vyepti |
| Eisai INC. | $370.73 | 2022-2024 | |
| Impel Pharmaceuticals INC. | $272.25 | 2022-2023 | Trudhesa |
| Allergan, INC. | $260.15 | 2019-2022 | |
| Pfizer INC. | $242.46 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $240.50 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $234.25 | 2022 | |
| Ucb, INC. | $207.96 | 2019-2024 | Zilbrysq |
| Genentech USA, INC. | $157.43 | 2021-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $151.69 | 2021-2023 | Ultomiris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $128.29 | 2023-2024 | Zeposia |
| Sk Life Science, INC. | $113.35 | 2022-2024 | |
| Avanir Pharmaceuticals, INC. | $102.32 | 2021-2022 | |
| Emd Serono, INC. | $88.13 | 2023-2024 | Mavenclad |
| Amneal Pharmaceuticals LLC | $79.74 | 2022-2023 | Rytary |
| Biohaven Pharmaceuticals, INC. | $70.61 | 2021 | |
| Banner Life Sciences, LLC | $68.22 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.49 | 2023-2024 | Hyqvia, Gammagard |
| Scilex Pharmaceuticals INC. | $44.89 | 2023 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $42.96 | 2023 | Rexulti, Nuedexta |
| Kyowa Kirin, INC. | $22.42 | 2024 | Nourianz |
| Upsher-Smith Laboratories LLC | $22.31 | 2023 | |
| Alnylam Pharmaceuticals INC. | $22.14 | 2024 | Amvuttra |
| Neurocrine Biosciences, INC. | $21.32 | 2023 | Ongentys, Ingrezza |
| Tg Therapeutics, INC. | $20.62 | 2023 | |
| Genzyme Corporation | $19.30 | 2023 | |
| Collegium Pharmaceutical, INC. | $16.43 | 2022 | |
| Boston Scientific Corporation | $13.22 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.